1258

JACC March 8, 2022

Volume 79, Issue 9, suppl A

Multimodality Imaging
ECHOCARDIOGRAPHIC PARAMETERS AS PREDICTORS OF DIURETIC RESPONSE IN PATIENTS
WITH ACUTE CARDIORENAL SYNDROME
Poster Contributions
For exact presentation time, refer to the online ACC.22 Program Planner at https://www.abstractsonline.com/pp8/#!/10461

Session Title: Multimodality Imaging Flatboard Poster Selections: Echo

Abstract Category: 27. Multimodality Imaging: Echo

Authors: Hong-Ju Kim, Jang-Won Son, Jong Ho Nam, Kang-Un Choi, Yeungnam University Medical Center, Daegu, South Korea
Background: Cardio-renal syndrome(CRS) is a clinical situation that combines cardiac and renal dysfunction. In acute CRS(Type I CRS),
diuretics administration is used for decongestion. However, in some cases, renal function worsens even after diuretics administration. This
study aimed to identify echocardiographic parameters to predict the diuretic response in Type I CRS.
Methods: The study was conducted on patients from 2012 to 2020 who were admitted for heart failure reduced ejection fraction (EF≤40%)
with renal dysfunction (eGFR<60). Blood tests and echocardiography were performed before diuretics administration, and a follow-up blood
test was performed.

Results: A total of 121 people were divided into 69 people in the non-improvement group and 52 people in the improvement group. PS
matching was used to correct the difference between the two groups. Among echocardiographic parameters, LVEDD(62.30±7.76 vs
57.60±8.52, p=0.005), LVESD(55.17±7.68 vs 48.35±8.38, p=0.000), LV ejection fraction(LVEF, %, 21.83±5.25 vs 27.27±8.32, p=0.000),
and Tissue doppler e’ velocity (TDI E’, 3.98±1.55 vs 5.13±1.82, p=0.002) showed significant differences. However, only LVEF and TDI E’
showed a statistically significant difference in multivariate logistic regression analysis (LVEF : OR=1.128(1.043-1.220, p-value=0.002), TDI
E’ : OR=1.462(1.088-1.964, p-value=0.012)).

Conclusion: Our study expected that higher LVEF and TDI E’ could predict diuretic response and efficacy in Type I CRS patients.